Praluent (alirocumab; Sanofi/Regeneron) is a fully human monoclonal antibody that inhibits PCSK9 and is intended for the treatment of hypercholesterolemia. PCSK9 is a protease involved in the intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. It binds to the epidermal growth factor-like repeat A domain of the LDLR and targets the receptor for lysosomal degradation within hepatocytes. PCSK9 is also known to increase the production of apolipoprotein B-containing lipoproteins. Praluent prevents circulating PCSK9 from binding to LDLRs, consequently inhibiting degradation. This allows the receptors to be recycled to the surface of hepatocytes, thus increasing plasma clearance of LDL-C.
LIST OF FIGURES
9 Figure 1: LDL-C lowering in pivotal trials of PCSK9 inhibitors Repatha and Praluent
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Praluent for dyslipidemia
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Praluent for dyslipidemia
18 Figure 4: Praluent sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2018–27
LIST OF TABLES
6 Table 1: Recent high-impact events for Praluent in dyslipidemia
7 Table 2: Praluent drug profile
8 Table 3: Approval history of Praluent for dyslipidemia in the US, Japan, and five major EU markets
9 Table 4: PCSK9 inhibitors, Repatha and Praluent, cardiovascular outcomes (hazard ratios vs placebo)
10 Table 5: Clinical trials for Praluent in dyslipidemia
13 Table 6: Praluent for dyslipidemia – SWOT analysis
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726